THE ROLE OF CYTOKINES IN HEMOLYTIC TRANSFUSION REACTIONS

被引:12
作者
DAVENPORT, RD
机构
[1] Department of Pathology, University of Michigan Medical School, Ann Arbor, MI
关键词
D O I
10.3109/08820139509062782
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Experimental evidence is accumulating to support a central role for cytokines in the pathophysiology of hemolytic transfusion reactions. The production of tumor necrosis factor, interleukin-8, and monocyte chemoattractant protein occurs in whole blood in response to ABO incompatible red cells, a model of acute hemolytic transfusion reactions. Peripheral blood mononuclear cells may produce interleukin-1 beta, tumor necrosis factor, interleukin-8, monocyte chemoattractant protein, and interleukin-1 receptor antagonist in response to IgG-coated red cells, a model of delayed hemolytic transfusion reactions. Cultured umbilical vein endothelial cells respond to conditioned plasma from ABO-incompatibility reactions by expressing the procoagulant tissue factor and the leukocyte adhesion molecules ELAM-1 and ICAM-1. These in vitro endothelial cell responses can be inhibited by neutralizing antibodies to tumor necrosis factor, suggesting that TNF may have a central role in intravascular coagulation and end-organ injury that may occur in acute hemolytic transfusion reactions.
引用
收藏
页码:319 / 331
页数:13
相关论文
共 26 条
[1]   INTERLEUKIN-6 IN BIOLOGY AND MEDICINE [J].
AKIRA, S ;
TAGA, T ;
KISHIMOTO, T .
ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 :1-78
[2]   INTERLEUKIN-1 RECEPTOR ANTAGONIST [J].
AREND, WP .
ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 :167-227
[3]   SYSTEMIC RELEASE OF NEUTROPHIL ELASTASE AND TUMOR-NECROSIS-FACTOR-ALPHA FOLLOWING ABO INCOMPATIBLE BLOOD-TRANSFUSION [J].
BUTLER, J ;
PARKER, D ;
PILLAI, R ;
SHALE, DJ ;
ROCKER, GM .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 (03) :525-526
[4]   INTERLEUKIN 1-INDUCED PATHO-PHYSIOLOGY - INDUCTION OF CYTOKINES, DEVELOPMENT OF HISTOPATHOLOGIC CHANGES, AND IMMUNOPHARMACOLOGIC INTERVENTION [J].
BUTLER, LD ;
LAYMAN, NK ;
CAIN, RL ;
RIEDL, PE ;
MOHLER, KM ;
BOBBITT, JL ;
BELAGAJIE, R ;
SHARP, J ;
BENDELE, AM .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1989, 53 (03) :400-421
[5]   CLINICAL-PHARMACOLOGY OF RECOMBINANT HUMAN-TUMOR NECROSIS FACTOR IN PATIENTS WITH ADVANCED CANCER [J].
CHAPMAN, PB ;
LESTER, TJ ;
CASPER, ES ;
GABRILOVE, JL ;
WONG, GY ;
KEMPIN, SJ ;
GOLD, PJ ;
WELT, S ;
WARREN, RS ;
STARNES, HF ;
SHERWIN, SA ;
OLD, LJ ;
OETTGEN, HF .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (12) :1942-1951
[6]   CYTOKINE PRODUCTION IN IGG-MEDIATED RED-CELL INCOMPATIBILITY [J].
DAVENPORT, RD ;
BURDICK, M ;
MOORE, SA ;
KUNKEL, SL .
TRANSFUSION, 1993, 33 (01) :19-24
[7]   MONOCYTE CHEMOATTRACTANT PROTEIN-PRODUCTION IN RED-CELL INCOMPATIBILITY [J].
DAVENPORT, RD ;
BURDICK, M ;
STRIETER, RM ;
KUNKEL, SL .
TRANSFUSION, 1994, 34 (01) :16-19
[8]   IN-VITRO PRODUCTION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN IGG-MEDIATED RED-CELL INCOMPATIBILITY [J].
DAVENPORT, RD ;
BURDICK, MD ;
STRIETER, RM ;
KUNKEL, SL .
TRANSFUSION, 1994, 34 (04) :297-303
[9]   RED-CELL ABO INCOMPATIBILITY AND PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA [J].
DAVENPORT, RD ;
STRIETER, RM ;
KUNKEL, SL .
BRITISH JOURNAL OF HAEMATOLOGY, 1991, 78 (04) :540-544
[10]  
DAVENPORT RD, 1990, BLOOD, V76, P2439